Skip to main content

Table 3 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to age of patients

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Urinary symptoms
(not at all = 0 to quite a lot = 5)
Total <65 years >65 years P value between groups r
Worry      
 Frequency 3.2 (3.1-3.3) 3.2 (3.1-3.3) 3.3 (3.1-3.4) 0.325 0.056
 Incontinence during sexual attempt 2.2 (2.2-2.3) 2.3 (2.2-2.4) 2.0 (1.9-2.2) 0.008 −0.128
 Nocturia 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.1 (3.0-3.3) 0.051 0.104*
 Frequency of infections 2.4 (2.3-2.5) 2.4 (2.2-2.5) 2.4 (2.2-2.5) 0.923 0.022
 Urgency 3.2 (3.1-3.3) 3.2 (3.1-3.3) 3.3 (3.1-3.4) 0.585 0.044
 Bladder pain 2.3 (2.3-2.4) 2.3 (2.2-2.4) 2.4(2.2-2.5) 0.775 0.034
 Urge incontinence 3.1 (3.0-3.3) 3.1 (2.9-3.2) 3.2 (3.1-3.3) 0.211 0.055
 Urinary difficulties 2.2 (2.1-2.3) 2.1 (2.0-2.2) 2.3 (2.2-2.4) 0.070 0.141
 Stress incontinence 2.2 (2.1-2.3) 2.1 (2.0-2.2) 2.2 (2.1-2.4) 0.266 0.028
Bother      
 Urinary frequency 3.2 (3.2-3.3) 3.2 (3.1-3.3) 3.3 (3.2-3.4) 0.453 0.029
 Strong desire to urinate 3.3 (3.2-3.4) 3.3 (3.1-3.4) 3.3 (3.2-3.4) 0.642 0.022
 Urine loss associated with a strong desire to urinate 3.1 (3.0-3.2) 3.1 (2.9-3.2) 3.2 (3.1-3.3) 0.117 0.055
Interference with daily-living activities     
 Usual activities 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.1 (2.9-3.2) 0.519 0.034
 Leisure 3.1 (3.0-3.2) 3.1 (3.0-3.2) 3.1 (3.0-3.2) 0.761 −0.005
 Work/domestic activities 2.5 (2.4-2.6) 2.7 (2.6-2.8) 2.2 (2.0-2.3) <0.001 −0.197
  1. p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence Interval) Pearson coefficient of correlation between symptom score and age. *p < 0.05; ‡p ≤ 0.001.